ALPS Advisors
DOVA

ALPS Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

ALPS Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-49,907
Closed -$1.05M – 988
2018
Q3 		$1.05M Buy
49,907
+8,998
+22% +$214K 0.01% 382
2018
Q2 		$1.22M Buy
+40,909
New +$1.11M 0.01% 297

Other funds holding DOVA

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Broadfin Capital
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fosun International
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ALPS Advisors's DOVA Position: Q4 2018 in Review

ALPS Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2018, closing a stake of 49,907 shares — an estimated $1.05M sold.

ALPS Advisors first reported a position in DOVA in Q2 2018 and held it in 2 quarters. The position peaked at $1.22M in Q2 2018. 58 funds tracked by Wall St. Rank hold DOVA as of Q4 2018.

  • ALPS Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 49,907 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $1.05M.
  • ALPS Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • ALPS Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.